期刊文献+

乳腺癌激素受体表达与新辅助化疗后病理完全缓解的关系 被引量:2

Relationship between Hormone Receptor Expression in Breast Cancer and Pathologic Complete Response after Neoadjuvant Chemotherapy
下载PDF
导出
摘要 目的:探讨乳腺癌激素受体表达与新辅助化疗(neoadjuvant chemotherapy,NCT)后病理完全缓解(pathologic complete response,pCR)的关系,指导筛选对化疗敏感的个体。方法:选取笔者所在医院2015年1月-2019年9月收治的102例接受NCT的激素受体阳性的乳腺癌患者作为研究对象,使用免疫组化方法检测NCT前乳腺癌患者的ER、PR表达情况,NCT结束后对手术标本采用Miller-Payne病理评价,分析激素受体的表达与pCR关系。结果:ER<50%组的乳腺癌患者pCR率为66.7%,明显高于ER≥50%组的28.7%,差异有统计学意义(χ^2=8.165,P=0.004)。ER<50%且PR<50%组患者pCR率为69.2%,明显高于其他组,差异有统计学意义(P<0.05)。PR<50%组的乳腺癌患者pCR率为36.6%,PR≥50%组乳腺癌患者pCR率为32.8%,两组比较差异无统计学意义(P>0.05)。结论:激素受体阳性型乳腺癌pCR与ER表达情况有关,与PR表达情况无关。 Objective:To explore the relationship between hormone receptor expression in breast cancer and pathologic complete response(pCR)after neoadjuvant chemotherapy(NCT),and to guide the screening of individuals sensitive to chemotherapy.Method:A total of 102 patients with hormone receptor positive breast cancer who received NCT in our hospital from January 2015 to September 2019 were selected as the research objects.Immunohistochemical method was used to detect the expression of ER and PR in breast cancer patients before NCT.After the end of NCT,Miller-Payne pathological evaluation was performed on the surgical specimens.The relationship between the expression of hormone receptor and pCR was analyzed.Result:The pCR rate of breast cancer patients in the ER<50%group was 66.7%,which was significantly higher than 28.7%in the ER≥50%group,and the difference was statistically significant(χ^2=8.165,P=0.004).The pCR rate of patients in the ER<50%and PR<50%group was 69.2%,which was significantly higher than that of other groups,and the difference was statistically significant(P<0.05).The pCR rate of breast cancer patients in the PR<50%group was 36.6%,and the pCR rate of breast cancer patients in the PR≥50%group was 32.8%,and there was no statistically significant difference between the two groups(P>0.05).Conclusion:The pCR of hormone receptor positive breast cancer is related to ER expression and not to PR expression.
作者 颜翔鹏 吕艳丽 穆为民 李毅 YAN Xiangpeng;LYU Yanli;MU Weimin;LI Yi(Beijing Shunyi District Maternal and Child Health Hospital,Beijing 101300,China;不详)
出处 《中外医学研究》 2020年第23期64-66,共3页 CHINESE AND FOREIGN MEDICAL RESEARCH
关键词 乳腺癌 激素受体 新辅助化疗 PCR Breast cancer Hormone receptor Neoadjuvant chemotherapy pCR
  • 相关文献

参考文献2

二级参考文献18

  • 1Viale G,Regan MM,Maiorano E,et al.Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer:BIG 1-98[J].J Clin Oncol,2007,25(25):3846-3852.
  • 2Rhodes A,Jasani B,Balaton AJ,et al.Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas:Correlation with patient age,assay sensitivity,threshold value,and mammographic screening[J].J Clin Pathol,2000,53(9):688-696.
  • 3Zhang Z,Wang J,Skinner KA,et al.Pathological features and clinical outcomes of breast cancer according to levels of oestrogen receptor expression[J].Histopathology,2014,65(4):508-516.
  • 4Harvey JM,Clark GM,Osbome CK,et al.Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer[J].J Clin Oncol,1999,17(5):1474-1481.
  • 5Elledge RM,Green S,Pugh R,et al.Estrogen receptor(ER)and progesterone receptor(PgR),by ligand-binding assay compared with ER,PgR and pS2,by immunohistocheniistiy in predicting response to tamoxifen in metastatic breast cancer:A Southwest Oncology Group study[J].Int J Cancer,2000,89?2):111-117.
  • 6Hammond ME,Hayes DF,Dowsett M,et al.American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J].J Clin Oncol,2010,28(16):2784-2795.
  • 7Wolff AC,Hammond ME,Schwartz JN,et al.American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[J].J Clin Oncol,2007,25(1):118-145.
  • 8Goldhirsch A,Winer EP,Coates AS,et al.Personalizing the treatment of women with early breast cancer:highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013[J].Ann Oncol,2013,24(9);2206-2223.
  • 9Taylor CR,Levenson RM.Quantification of immunohistochemistry:Issues concerning methods,utility and semiquantitative assessment II[J].Histopathology,2006,49(4):411-424.
  • 10Yaziji H,Taylor CR,Goldstein NS,et al.Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry[J].Appl Immunohistochem Mol Morphol,2008,16(6):513-520.

共引文献1398

同被引文献37

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部